Opioid use disorder: current trends and potential treatments

Front Public Health. 2024 Jan 25:11:1274719. doi: 10.3389/fpubh.2023.1274719. eCollection 2023.

Abstract

Opioid use disorder (OUD) is a major public health threat, contributing to morbidity and mortality from addiction, overdose, and related medical conditions. Despite our increasing knowledge about the pathophysiology and existing medical treatments of OUD, it has remained a relapsing and remitting disorder for decades, with rising deaths from overdoses, rather than declining. The COVID-19 pandemic has accelerated the increase in overall substance use and interrupted access to treatment. If increased naloxone access, more buprenorphine prescribers, greater access to treatment, enhanced reimbursement, less stigma and various harm reduction strategies were effective for OUD, overdose deaths would not be at an all-time high. Different prevention and treatment approaches are needed to reverse the concerning trend in OUD. This article will review the recent trends and limitations on existing medications for OUD and briefly review novel approaches to treatment that have the potential to be more durable and effective than existing medications. The focus will be on promising interventional treatments, psychedelics, neuroimmune, neutraceutical, and electromagnetic therapies. At different phases of investigation and FDA approval, these novel approaches have the potential to not just reduce overdoses and deaths, but attenuate OUD, as well as address existing comorbid disorders.

Keywords: electrical stimulation of the brain; hallucinogens; homeostasis; neuroimmunomodulation; opioid-related disorders; pro-dopamine-regulation; public health; therapeutics.

Publication types

  • Review

MeSH terms

  • Buprenorphine* / therapeutic use
  • Drug Overdose* / drug therapy
  • Drug Overdose* / prevention & control
  • Humans
  • Naloxone / therapeutic use
  • Opiate Substitution Treatment
  • Opioid-Related Disorders* / drug therapy
  • Pandemics

Substances

  • Buprenorphine
  • Naloxone

Grants and funding

The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.